- Home
- EQX vs ARWR Comparison
EQX vs ARWR Comparison
Compare EQX & ARWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQX
- ARWR
- Stock Information
- Founded
- EQX 2007
- ARWR 2003
- Country
- EQX Canada
- ARWR United States
- Employees
- EQX N/A
- ARWR N/A
- Industry
- EQX Precious Metals
- ARWR Biotechnology: Pharmaceutical Preparations
- Sector
- EQX Basic Materials
- ARWR Health Care
- Exchange
- EQX Nasdaq
- ARWR Nasdaq
- Market Cap
- EQX 3.2B
- ARWR 1.8B
- IPO Year
- EQX N/A
- ARWR 1993
- Fundamental
- Price
- EQX $5.81
- ARWR $16.79
- Analyst Decision
- EQX
- ARWR Buy
- Analyst Count
- EQX 0
- ARWR 8
- Target Price
- EQX N/A
- ARWR $43.71
- AVG Volume (30 Days)
- EQX 18.2M
- ARWR 1.5M
- Earning Date
- EQX 08-06-2025
- ARWR 08-07-2025
- Dividend Yield
- EQX N/A
- ARWR N/A
- EPS Growth
- EQX N/A
- ARWR N/A
- EPS
- EQX 0.64
- ARWR N/A
- Revenue
- EQX $1,696,526,000.00
- ARWR $545,209,000.00
- Revenue This Year
- EQX $40.61
- ARWR $21,924.50
- Revenue Next Year
- EQX $14.56
- ARWR N/A
- P/E Ratio
- EQX $14.36
- ARWR N/A
- Revenue Growth
- EQX 54.88
- ARWR 1436.97
- 52 Week Low
- EQX $4.48
- ARWR $9.57
- 52 Week High
- EQX $7.45
- ARWR $30.41
- Technical
- Relative Strength Index (RSI)
- EQX 37.70
- ARWR 60.13
- Support Level
- EQX $5.66
- ARWR $15.33
- Resistance Level
- EQX $5.95
- ARWR $16.76
- Average True Range (ATR)
- EQX 0.20
- ARWR 0.76
- MACD
- EQX -0.05
- ARWR 0.03
- Stochastic Oscillator
- EQX 16.89
- ARWR 82.67
About EQX Equinox Gold Corp.
Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.
About ARWR Arrowhead Pharmaceuticals Inc.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.